SMC approves Viekirax and Exviera for the treatment of Hepatitis C in Scotland
Today the Scottish Medicines Consortium (SMC) has announced that they have approved ombitasvir/paritaprevir/ritonavir (Viekirax®) and dasabuvir (Exviera®) for use within NHS Scotland.
Both products are made by Abbvie Ltd and provide patients and clinicians with more choice in providing the new, interferon-free, Direct Acting Antivials (DAAs). You can read the full advice on the SMC website. These new products join the four other therapies already approved for use in Scotland.
SMC approval gives the 14 Regional Health Boards in Scotland permission to use a product but it doesn’t mean that they have to use it.
The vast majority of people with bleeding disorders in Scotland who have asked for a new DAA treatment for Hepatitis C have been given access to the treatments. If you are seeking treatment, going through treatment, or have completed treatment then we’d like to hear from you. Please call the office or email Dan Farthing-Sykes.